SNGX: Soligenix, Inc. Stock

by  •  • Comments Off on SNGX: Soligenix, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 5.65
Enterprise Value ($M) -2.13
Book Value ($M) 5.94
Book Value / Share 2.37
Price / Book 0.95
NCAV ($M) 5.77
NCAV / Share 2.30
Price / NCAV 0.98

Profitability (mra)
Return on Invested Capital (ROIC) -0.87
Return on Assets (ROA) -0.72
Return on Equity (ROE) -2.81

Liquidity (mrq)
Quick Ratio 2.28
Current Ratio 2.28

Balance Sheet (mrq) ($M)
Current Assets 10.31
Assets 10.48
Liabilities 4.54
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)
Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 ☐TRANSITION REPORT PURSUANT T
2024-08-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 ☐TRANSITION REPORT PURSUANT TO SEC
2024-05-10 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 ☐TRANSITION REPORT PURSUANT TO SE
2024-03-15 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the Fiscal Year Ended December 31, 2023 ☐TRANSITION REPORT PURSUAN

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-02-04 8,905 28,469 31.28
2025-02-03 12,797 49,970 25.61
2025-01-31 11,206 25,026 44.78
2025-01-30 6,556 33,616 19.50

(click for more detail)

Similar Companies
SLRX – Salarius Pharmaceuticals, Inc. SLS – SELLAS Life Sciences Group, Inc.
SNDL – SNDL Inc. SNPX – Synaptogenix, Inc.
SNSE – Sensei Biotherapeutics, Inc.


Financial data and stock pages provided by
Fintel.io